Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity (Q37483205)

20 August 2017

1 reference

title

Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity (English)

1 reference

20 August 2017

endocannabinoid system

0 references

obesity

0 references

author name string

Carlos E Leite

1

1 reference

20 August 2017

Clei A Mocelin

2

1 reference

20 August 2017

Guilherme O Petersen

3

1 reference

20 August 2017

Mirna B Leal

4

1 reference

20 August 2017

Flavia V Thiesen

5

1 reference

20 August 2017

1 March 2009

1 reference

20 August 2017

Pharmacological Reports

1 reference

20 August 2017

61

1 reference

20 August 2017

217-224

1 reference

20 August 2017

2

1 reference

New targets for obesity pharmacotherapy

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Efficacy and safety of the weight-loss drug rimonabant

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Leptin-regulated endocannabinoids are involved in maintaining food intake

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

[The endocannabinoid system: a new paradigm in the metabolic syndrome treatment]

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Weight loss maintenance in women two to eleven years after participating in a commercial program: a survey

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Obesity: which drug and when?

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Depression and anxiety with rimonabant

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

How many sites of action for endocannabinoids to control energy metabolism?

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

The emerging role of the endocannabinoid system in endocrine regulation and energy balance

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Cannabinoids and the regulation of ingestive behaviour

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Psychosocial aspects of obesity and obesity surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

Rimonabant: endocannabinoid inhibition for the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2809%2970025-8

7 January 2021

10.1016/S1734-1140(09)70025-8

Identifiers

DOI

1 reference

20 August 2017

1 reference